Objective: The Children's Oncology Group study AREN0534 aimed to improve event-free survival (EFS) and overall survival (OS) while preserving renal tissue by intensifying preoperative chemotherapy, completing definitive surgery by 12 weeks from diagnosis, and modifying postoperative chemotherapy based on histologic response. Background: No prospective therapeutic clinic trials in children with bilateral Wilms tumors (BWT) exist. Historical outcomes for this group were poor and often involved prolonged chemotherapy; on NWTS-5, 4-year EFS for all children with BWT was 56%. Methods: Patients were enrolled and imaging studies were centrally reviewed to assess for bilateral renal lesions. They were treated with 3-drug induction chemotherapy (vincristine, dactinomycin, and doxorubicin) for 6 or 12 weeks based on radiographic response followed by surgery and further chemotherapy determined by histology. Radiation therapy was provided for postchemotherapy stage III and IV disease. Results: One hundred eighty-nine of 208 patients were evaluable. Four-year EFS and OS were 82.1% (95% CI: 73.5%-90.8%) and 94.9% (95% CI: 90.1%-99.7%. Twenty-three patients relapsed and 7 had disease progression. After induction chemotherapy 163 of 189 (84.0%) underwent definitive surgical treatment in at least 1 kidney by 12 weeks and 39% retained parts of both kidneys. Surgical approaches included: unilateral total nephrectomy with contralateral partial nephrectomy (48%), bilateral partial nephrectomy (35%), unilateral total nephrectomy (10.5%), unilateral partial nephrectomy (4%), and bilateral total nephrectomies (2.5%). Conclusion: This treatment approach including standardized 3-drug preoperative chemotherapy, surgical resection within 12 weeks of diagnosis and response and histology-based postoperative therapy improved EFS and OS and preservation of renal parenchyma compared with historical outcomes for children with BWT.
T he outcome for patients with unilateral favorable histology Wilms tumor is excellent with event free survival (EFS) greater than 85%. [1] [2] [3] [4] However, patients with bilateral Wilms tumor (BWT) have significantly poorer results. On National Wilms Tumor Study 5 (NWTS-5), the 4-year EFS estimates for all patients with BWT was 56% (95% CI: 44.8%-66.6%); for patients with favorable histology, focal anaplastic, and diffuse anaplastic BWT, 4-year estimates were 65% (with retention of heterozygosity at 1p), 76% and 25%, respectively. [5] [6] [7] The Socie?te? Internationale d'Oncologie Pe?diatrique (SIOP) reported a 10-year overall survival (OS) of just 69% for patients with synchronous BWT treated with either preoperative radiotherapy and/or chemotherapy. [8] [9] [10] Both also reported several late deaths from disease recurrence more than 3 years after diagnosis. 11 End-stage renal disease (ESRD) rates in children with BWT are also higher as compared with those with unilateral tumors. 12, 13 The 20-year cumulative incidence of ESRD for survivors of unilateral Wilms Tumor (WT) was less than 1% (0.6% in nonsyndromic children), whereas the rate in children with BWT was 12% and much higher in children with genetic syndromes such as Denys Drash Syndrome (75%) or the Wilms Tumor-Aniridia-Genitourinary Malformation-Mental Retardation Syndrome (50%). In the patients with BWT who had ESRD within 5 years after treatment the cause was a second nephrectomy in (30/32) 94% whereas it was only 50% of cases in the children who had ESRD after 5 years. 12 Several factors are thought to contribute to the unfavorable outcomes in patients with BWT. [14] [15] [16] These include under-staging resulting in under-treatment, delay in local disease control, and increased incidence of anaplasia. Biopsy, both open wedge and core needle methods, often fails to identify focal or diffuse anaplastic histology. 16 This has resulted in some patients being treated for extended periods of time without effect. Shamberger et al 14 showed that children with BWT received chemotherapy regimens that lasted From the between 37 and 50 weeks exposing them to both acute and long-term toxic events but with no effect on renal preservation or overall treatment outcome. It has also been shown that in some patients a tumor may not change in size on radiographic imaging or may slightly increase after chemotherapy because the tumor had differentiated or undergone rhabdomyomatous changes. 17 While these patients have excellent survival, their tumors will not regress in size with further chemotherapy.
The success in treating unilateral WT has been the direct result of several large controlled trials by the research consortia in North America, the United Kingdom, and Europe. 3 These studies have defined surgical, radiotherapy, and chemotherapy regimens in other stages of WT. However, no prospective clinical trial with defined treatment regimens for BWT has been reported.
To improve outcomes for children with BWT, the Children's Oncology Group (COG) opened study AREN0534 in 2009. 18 The primary aims related to BWT were to improve 4-year EFS to 73% for patients with BWT, to prevent complete removal of at least 1 kidney in 50% of patients with BWT by using prenephrectomy 3-drug chemotherapy with vincristine, dactinomycin, and doxorubicin, and to have at least 75% of children with BWT undergo definitive surgical treatment by 12 weeks after initiation of chemotherapy. The purpose of this paper is to present the results of these primary aims.
METHODS

Study
The COG study AREN0534, ''Treatment for Patients with Bilateral, Multi-centric, or Bilaterally-Predisposed Unilateral Wilms Tumor'' had 3 arms: 1 for treatment of patients with BWT, 1 for patients with unilateral tumors at high-risk for metachronous disease or multicentric tumors, and 1 for patients with diffuse hyperplastic perilobar nephroblastomatosis. 18 This report presents the results of children with BWT.
Enrollment and Eligibility
Local institutional review board or research ethics board approval of this study was obtained prior to enrolling patients. Patients had to be < 30 years old at the time of initial diagnosis and had to have synchronous bilateral renal masses 1 cm or greater on radiographic imaging. All patients were first enrolled on the COG biology and classification study AREN03B2. Patients could enroll without a diagnostic biopsy (the majority), with a diagnostic biopsy or after definitive surgery. Before enrollment on the therapeutic study AREN0534, real-time central review of diagnostic imaging, pathology (if obtained), and operative notes confirmed the status of BWT. [19] [20] [21] Enrollment was required within 14 days of diagnosis or 7 days after starting therapy. Due to the difficulty of distinguishing WT from a nephrogenic rest based on imaging studies and percutaneous biopsies, the guideline was established that a child with a single renal lesion 1 cm or greater in size in the contralateral kidney or multiple lesions (of any size) in the contralateral kidney should be treated on the synchronous BWT stratum. Patients with an isolated lesion less than 1 cm in the contralateral kidney should be treated by nephrectomy with postoperative therapy based on the pathologic findings. These patients could have been enrolled in another therapeutic study.
18,22
Staging
Patients with BWT received both a local stage and an overall disease stage. The final local stage was based on the abdominal tumor burden, whereas the disease stage accounted for the presence of distant metastatic disease. The COG and SIOP staging systems have been well described. 23 The highest local stage is III and disease stage is IV. Patients treated with preoperative chemotherapy without undergoing biopsy were staged according to the staging system used by SIOP. 24 
Treatment
The overall strategy of the study was to administer prenephrectomy chemotherapy with the goal to perform bilateral partial nephrectomies. Initial induction therapy included vincristine, dactinomycin, and doxorubicin (regimen VAD) for 2 cycles 3 weeks per cycle (dosing and regimen in supplemental files, http://links. lww.com/SLA/B311). After 6 weeks, cross-sectional imaging was performed and a tumor response was assigned for each kidney (see response criteria below). If it was deamed feasible by the local institution to perform bilateral partial nephrectomies, surgery was to be undertaken. If the tumors achieved a partial response (PR) but
were not yet amendable to bilateral partial nephrectomy, chemotherapy was continued for another 2 cycles. If tumors in either kidney did not achieve a PR, bilateral open renal biopsies were performed to assess the histologic reason for nonresponsiveness. After 4 cycles of VAD (12 weeks), repeat cross sectional imaging was performed and definitive surgery was required.
Radiology Response Criteria
Criteria used to assess tumor response included reduction in size and the ability to perform a nephron-sparing procedure. Response was based on the Response Evaluation Criteria in Solid Tumor (RECIST 1.1) modified to include 3 lesions per kidney. 25 Target lesions were defined as lesions greater than 10 mm within the kidney. If multiple target lesions were present at least 3 of them were described. Overall response was not modified by extra renal target lesions nor nontarget disease. Each kidney was assessed separately. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (which equals to a 50% decrease in volume), taking as reference the baseline sum diameters. Progressive disease (PD) was defined as at least a 20% increase in the sum of the diameters of target lesions and stable disease (SD) as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Chemotherapy
Adjuvant therapy was based on tumor stage and histologic response after either 6 or 12 weeks of chemotherapy. Table 1  describes the chemotherapy regimens and Tables 2A, 2B , 2C shows the treatment strategy for patients with BWT at initial diagnosis, week 6 and week 12 (dosing in supplemental files, http://links. lww.com/SLA/B311). The final risk stratification based on postsurgery and chemotherapy pathology used by SIOP. 23 The details of the chemotherapy regimens have been used in prior studies; however in the recent studies the regimens changed with respect to mg/kg versus mg/m 2 dosing (VAD, EE4A, DD4A, I and revised UH-1 (supplemental files, http://links.lww.com/SLA/B311). [26] [27] [28] Treatment was based on the kidney with the highest stage. For example, if 1 kidney was stage I and the other stage III, chemotherapy treatment was based on the stage III.
Radiation Therapy
For favorable histology tumors that were classified as abdominal stage III, flank radiotherapy with 10.8 Gy was utilized (19.8 Gy for !16 yr old). A difference from other COG studies for unilateral Wilms tumor was that although needle or biopsies prior to chemotherapy were considered a criterion for stage III, these patients were not mandated to receive flank radiation therapy if there were no other reasons for stage III designation. Patients requiring whole abdomen irradiation due to preoperative tumor rupture, peritoneal metastases, or a large intraoperative tumor spill affecting areas outside the tumor bed as determined by the surgeon received 10.5 Gy. A boost of 10.8 Gy was given to patients with residual disease. For patients with stage I and II anaplastic histology, radiation doses were the same as for favorable histology. However, higher doses (19.8 Gy flank or 10.5 Gy whole abdomen with a 9 Gy boost to the flank for patients requiring whole abdomen irradiation) were provided to patients with stage III diffuse anaplastic histology. Patients 12 months old requiring whole abdomen radiation therapy did not receive the boost to the flank. All patients with stage IV disease with pulmonary metastasis received whole lung irradiation to a dose of 12 Gy (10.5 Gy for patients < 12 mo old).
Statistical Considerations
The study was monitored by an independent data safety monitoring board. A target accrual of 234 patients was required to enroll a minimum of 115 eligible patients with favorable histology BWT without blastemal features to meet the study's statistical considerations. This minimal sample size provided 80% power [testing (using the 2-sample log-rank test) at the 5% level of statistical significance (1-sided)] to detect about a 43% reduction in the risk of failure in nonblastemal, favorable histology BWT (relative failure rate 0.57:1.00, corresponding to an increase in 4-year EFS to about 80%). Interim efficacy monitoring was done at 25%, 50%, and 75% of the expected information using an O'Brien-Fleming boundary (truncated at 3 standard deviations). 29 The other histological subsets were too small to detect definitively an improvement in their EFS and are presented using descriptive statistics. Statistical methods used included Fisher exact test and Kaplan-Meier estimates of the OS and EFS curves. 30 
RESULTS
Patient Characteristics
The study opened in July 2009 and closed in June 2015. Two hundred forty-nine patients were enrolled and 7 were declared inevaluable (1 failure to sign proper consent, 2 with incorrect pathology, 4 went off study because of investigator choice). There were 99 males and 143 females. Eighty percent of children presented before 48 months. 21.1% of the patients had a genetic syndrome as an underlying diagnosis. There were 9 children with hemihypertrophy, 7 Beckwith-Wiedemann Syndrome, 6 with Wilms Tumor-AniridiaGenitourinary Malformation-Mental Retardation Syndrome and 3 with Denys Drash Syndrome and 16 with an isolated anomaly. One hundred and ninety-five enrolled on the BWT strata, of which 163 had nonblastemal type, 13 had blastemal-type, and 19 unknown postchemotherapy histology. Five of 195 were declared inevaluable due to protocol violations related to chemotherapy delivery and 1 was excluded because the patient had rhabdoid pathology. Median follow-up was 3.75 years. Twenty-six had at least 1 kidney with anaplasia, 9 had focal anaplasia, and 17 had diffuse anaplasia. After induction chemotherapy and surgery, the local stage distribution (based on the kidney with the highest stage) was stage I (37.5%), stage II (14.4%), and stage III (48.1%). Twenty-seven (14.4%) of patients had stage IV disease (pulmonary metastasis in all cases). Thirteen patients had biopsies at time 0.
Tumor Response and Surgical Resection
The tumor response to prenephrectomy chemotherapy among 189 patients with BWT using the Response Evaluation Criteria in Solid Tumor for the least responsive tumors was complete response (8) , PR (121), SD (58), and PD (2). Of the 189 BWT patients, 163 (84.0%) underwent definitive surgical treatment (partial or complete nephrectomy or wedge resection in at least 1 kidney) by 12 weeks after initiation of chemotherapy (aim 3). Thirty percent of those patients who achieved definitive surgical resection within the 12 week specified aim did so by at the 6-week evaluation point. Surgical approaches included: unilateral total nephrectomy with contralateral partial nephrectomy (48%), bilateral partial nephrectomy (35%), unilateral total nephrectomy (10.5%), unilateral partial nephrectomy (4%), and bilateral total nephrectomies (2.5%).
Clinical Outcomes
For the 189 patients with BWT, the 4-year EFS and OS (aim 1) were 82.1% (95% CI: 73.5%-90.8%) and 94.9% (95% CI: 90.1%-99.7%) (Fig. 1 ). There were 23 (12%) relapses with a median time to relapse of 15.21 AE 10.7 (SD) months. Sixteen of 167 (9.5%) patients with favorable histology, 7 of 16 (43%) patients with diffuse anaplastic histology, and 0 of 7 patients with focal anaplastic histology relapsed. Three relapses occurred at multiple sites, 10 in the remaining kidney(s) alone, 7 in the lung alone, 1 in the liver alone, and 2 in the abdomen but not the renal fossa. Seven patients progressed on therapy, with 1 death.
The 4-year EFS and OS according to histology and stage are listed in Table 3 . Aim 2 was to prevent complete removal of at least 1 kidney in 50% of patients with BWT by using prenephrectomy 3-drug chemotherapy induction with vincristine, dactinomycin, and doxorubicin. Of the 163 who underwent surgery by 12 weeks, 143 had either 6 or 12 weeks of prenephrectomy chemotherapy. In this group 61% required complete nephrectomy of at least 1 kidney. The 20 other patients either had upfront surgery, surgery due to complications from disease progression or did not tolerate all the cycles of chemotherapy.
Toxicity
There were no grade 5 toxic events reports on the study. There were 4 cases of sinusoidal obstructive syndrome (VOD) in patients who received regimen DD4A as part of their postnephrectomy therapy. All 4 recovered.
DISCUSSION
The AREN0534 study successfully improved outcomes for patients with BWT, with 4-year EFS and OS estimates of 82.1% and 94.16%, as compared with 4-year EFS and OS estimates of 56% and 80.8% on NWTS-5. 7 Several interventions that were implemented on AREN0534 likely contributed to this improvement. First, chemotherapy was tailored according to postchemotherapy histologic response. Patients with anaplastic and blastemal-type histology received more intensive chemotherapy compared with previous studies. Although the number of patients in each subgroup was small, the results suggest improvement for both favorable and diffuse anaplastic histology. Four-year EFS for favorable histology went from 65% (reported for patients with retention of heterozygosity at chromosome 1p) on NWTS-5 to 84.1% on AREN0534. For diffuse anaplastic histology, 4-year EFS went from 25% on NWTS-5 to 58.2% on the current study. The 4-year EFS and OS estimates for patients with blastemal-type tumors were 82% and 91%, respectively. Although outcomes in this small group of patients were not assessed on NWTS-5, this result is promising based on the adverse prognostic significance of blastemal type reported on the SIOP studies. 31 It is possible that the survival estimates on AREN0534 will diminish over time based on observations from prior BWT reports that late relapses were common. 18 However, thus far, the majority of patients relapsed within the first 18 months following diagnosis, which leads us to believe that the excellent outcomes on AREN0534 will persist.
A second intervention implemented on AREN0534 was to decrease the time from diagnosis to surgical resection. Shamberger et al 14 studied 38 patients from NWTS 4 with progressive or nonresponsive disease. Preoperative chemotherapy was given for a median of 7 months (range, 2-29 mo) before definitive resection. Thirty-six children went on to a second regimen, and of these, 21 children received a third regimen before resection. Ten of the 38 patients lacked histology data and of the remaining 28 patients, 15 had either rhabdomyomatous differentiation, complete necrosis, or stromal differentiation. A tumor may also be nonresponsive because it has anaplastic histology which may be chemo-insensitive and requires early definitive surgery.
14 Furthermore, a review by the German Society of Pediatric Oncology and Hematology of patients with BWT reported that maximum tumor shrinkage occurred in the first 12 weeks of chemotherapy. 32 Based on these considerations, an aim of AREN0534 was for 75% of patients to undergo definitive surgery by 12 weeks. To facilitate earlier surgical resection, all patients received 3-drug therapy with vincristine/dactinomycin/ doxorubicin rather than starting with just vincristine/dactinomycin and escalating if response was inadequate. The choice to use 3 drugs was based on data from SIOP studies showing greater tumor shrinkage with 3-drug compared with 2-drug therapy. 23 Additionally, Paulino et al 33 found that a 3-drug regimen resulted in a significantly lower relapse rate (8%) compared with a 2-drug regimen (42%) in patients with synchronous BWT. AREN0534 exceeded its aim to expedite surgical resection, with 84% of patients having definitive surgical treatment by 12 weeks, with the majority of patients having a PR to chemotherapy.
Compared with patients with unilateral WT, children with BWT have poorer EFS and are at higher risk for later effects such as renal failure. 11, 12, 34, 35 An overriding goal was to improve EFS balanced with conservation of renal tissue. Our goal was to have at least 50% of patients undergo bilateral nephron-sparing surgery (NSS). We did not reach this threshold, with only 39% successfully treated with bilateral NSS. Davidoff et al reported a 13-year experience of 42 patients with BWT where he was able to perform bilateral NSS in 92% of patients. 36 Comparison of these 2 study populations without imaging has its limits but the data does suggest that surgeon experience may affect the chance of undergoing NSS. The aim might have been ambitious for a cooperative group-wide study. However, the NSS rate on AREN0534 was greater than what would be expected based on the NSS experience with unilateral WT. Interestingly, the Surveillance, Epidemiology, and End Results Program from the NCI reports a similar renal sparing rate. SIOP protocols routinely use prenephrectomy chemotherapy, with up to 85% of tumors responding to some degree but not necessarily resulting in NSS in unilateral lesions. [37] [38] [39] In the SIOP 2001 study, partial nephrectomies for unilateral WT were permitted if the tumor was polar or noninfiltrating by cross-sectional imaging, but only 3% of the total cases enrolled met these criteria for a partial nephrectomy after prenephrectomy chemotherapy. 40 In patients with bilateral lesions there is an increased effort at renal preservation to avoid renal failure, in contrast with patients with unilateral lesions in which there is much less concern for this issue. A recent technical paper on longitudinal partial nephrectomy by Fuchs to address central renal lesions may also increase the rate of NSS. 41 Other factors that may increase the NSS rates include regionalization of these patients to centers with more experience since these are rare cases and central review that includes technical guidance.
COG renal tumor studies require pathology prior to treatment and study enrollment. This study was an exception because patients could enroll based on imaging alone. The primary reasons to perform a biopsy at initial presentation are to avoid misdiagnosis of Wilms tumor and to detect anaplasia. The rate of misdiagnosis of Wilms tumor is low, between 1.6% and 5.5% for unilateral renal tumors on SIOP studies. 42 The rate is estimated to be even lower for bilateral renal tumors because bilateral non-Wilms renal tumors are very uncommon, though rare patients with bilateral rhabdoid tumor and renal cell carcinoma have been reported. 43 Regarding the detection of anaplasia, review of data from NWTS 4 showed that needle biopsy failed to detect anaplasia and open biopsy only detected them in one-third of cases. 15 On NWTS-5, among 25 patients with bilateral anaplastic Wilms tumor for whom biopsy and nephrectomy histology were available for review, only 2 (8%) had anaplasia detected in the initial biopsy sample. 5 Based on these considerations, patients could enroll on AREN0534 based on imaging alone with the caveat that in an unusual clinical situation that may suggest a diagnosis other than Wilms tumor, such as age > 10 years or atypical imaging features obtaining a tissue diagnosis before starting therapy should be considered.
The limitations of the study are inherent in its design. Although the EFS and OS reported here are improved compared with historical reports, this was not a randomized controlled trial and it is therefore difficult to pinpoint which factors played the greatest role in improving outcome. While radiographic criteria were well defined for this study, we cannot be certain that some of the smaller lesions that resolved with neoadjuvant therapy may have been nephrogenic rests. This may have resulted in the inclusion of patients with unilateral WT in the patient cohort. To mitigate this, we excluded patients with lesions less than a centimeter. It is difficult to estimate how this may affect results. In addition, a core or needle biopsy cannot discriminate between a rests ad tumor unless a rim of capsule or normal tissue is included in the sample. Wilms tumors arise from rests that become hyperplastic and can be considered premalignant. We do not feel that the main reason for the improved EFS and OS was that we were treating benign lesions. Second, the study is not yet mature enough to determine the impact of this treatment strategy on late effects such as renal failure or anthracycline toxicity. Patients will be followed for 10 years to track the renal failure rates. Future study will need to also focus on the impact of initial tumor burden to predict response, common factors predicting relapse including biomarkers such as 1q gain or LOH 1p and 16q, impact of novel agents to improve tumor response and directing further strategies toward renal preserving surgery.
The results of AREN0534 indicate that improved EFS and OS for patients with BWT can be achieved with real-time central review of imaging, surgery, and pathology, standardized 3-drug preoperative chemotherapy, surgical resection within 12 weeks of diagnosis and histology-based postoperative therapy. While the results provide benchmark outcomes for future studies, EFS can be improved and nephron-sparing surgery rates were suboptimal. In future studies, central review incorporating technical guidance for patients with BWT prior to definitive surgical may be useful. from them that their rate of misdiagnosis is probably somewhere between 1% and 4%. Second, the rate of misdiagnosis of a patient under the age of 5 not being bilateral Wilms tumor is exceedingly, exceedingly low. There was 1 patient from Asia of a report of bilateral clear cell sarcoma. Even in the event that that was the situation, the initial chemotherapy was the same for both of these patients regardless of what study they would have been on, even for unilateral.
Secondly, the second reason to perform a biopsy is to determine anaplasia, and needle biopsy simply cannot determine anaplasia. Needle biopsies cannot determine the difference between a benign and a malignant lesion because nephrogenic rests are different than Wilms tumor, but under a microscope you can't tell that difference unless you have normal kidney tissue and unless you have the capsule. To detect anaplasia, we know that needle biopsy will never detect it and open biopsies only detected it in a third of cases. So we felt it was reasonable to give that option.
Underlying all that was the idea that we know the patients who underwent biopsies in the past and then underwent nephrectomies had a higher recurrence rate. That was another paper by Dr Shamberger. Patients could enroll with a biopsy. They weren't penalized, but most agreed that it was unnecessary.
The second question on late effects has asked are we continuing to follow these patients? All patients will be followed on Children's Oncology Group studies for 10 years. Now, that will definitely be enough time to determine progression of the disease, particularly because in the first 5 years we'll know which ones have gone on to renal failure because of disease progression and maybe have some late effects but probably not enough for patients who got flank radiation who have 2 now and 30 years down the road.
There are 2 other ways that you can follow that. One is through the Wilms Tumor Late Effects Study, which has been funded continuously for about 25 years, and the other is the Children's Cancer Annual Late Effects Group that sends out a survey.
With regard to nephron-sparing surgery and regionalization, I'm not going to discuss the regionalization. I'm not going to go there. But it's clear that experience and understanding of the disease makes a difference. What a lot of people may have trouble understanding is that the tumor as opposed to renal cell carcinoma, which most cases replaces the kidney, the tumors tend to compress a lot of normal tissue. And what can look like it's unresectable and unavailable for a partial nephrectomy you can really peel out a lot of the times. There is also a capsule there, and you can go through that capsule, and that's not a positive margin.
I know that Dr Davidoff, Dr Shamberger, and myself, we get calls about this, and we try and educate people. A mandate I simply think is just ideal. It may not happen. It's going to happen in Europe but not here.
Dr Walter Chwals (Boston, MA):
I enjoyed the talk and congratulate you and COG and you for this presentation.
Relative to criteria for nephron-sparing surgery, has any COG committee considered structuring a guideline protocol which addresses when this type of surgery should be undertaken?
The second question is whether you have found that subspecialty training in pediatric surgery versus pediatric urology influences how frequently nephron-sparing surgery is performed.
Dr Peter F. Ehrlich (Ann Arbor, MI):
In terms of criteria, in the protocol there were guidelines on what would constitute a safe resection. That being said, because these tumors can look absolutely massive but compress a lot of normal tissue, those guidelines don't always apply to do that.
In terms of have we looked at who did the surgery, pediatric surgery versus not, I can't give you an exact number. I can give a rough idea that most of the urologists -most people say things are unresectable. A lot of them were urologists who sometimes do this. Pediatric urologist, there are only a couple who have a strong interest in pediatric oncology. So I think it was equally weighted to do that.
The central lesion is one area where things often look unresectable but are often able to be resectable in those situations. But underlying it all, the goal is to save the kid and not the kidney, and, clearly, with this protocol, or at least protocolizing it, we've gotten better outcomes to date than we did at the end of 2001.
Dr Thomas Tracy (Hershey, PA):
Thank you. Peter, again, I want to congratulate you on the excellent work and congratulate all the participants of the multidisciplinary trials that were able to bring this about and accrue as many patients as you did in such a short period of time.
One of the concerns that you brought up at the very end, and it's been questioned by Walt and the others, is how would you actually effect this central consultation?
When you look at this study can you compare it to those of our SIOP colleagues, with the kind of regionalization that they are able to provide and go even further than many of us are with collaborative teams that involved advanced urologic care as well as advanced pediatric surgical care? Part of the data points out that we may be a little bit behind those systems. I wonder if you would comment on the types of resections done in Europe. In other words, we had a high rate of unilateral nephrectomy; whereas, in many of these patients they don't require a nephrectomy at all.
You could compare and contrast both of those important studies, now this study with that study, with the kind of surgical resections done in STOP and how they were able to achieve the rates they did and how they've been doing it for so long. Thanks.
Thank you, Dr Tracy. I think to clarify, the results of any European study on bilateral Wilms tumor, they haven't done a study. They report results, and they haven't reported renal-sparing surgeries for bilateral Wilms tumor. Certain centers have reported theirs. And they tend to closely parallel what we saw in this study, not what Dr Davidoff had on his study to do that.
Some regionalization occurs in European centers. Exactly how is that done? The 1 country for sure that does regionalization is the Netherlands. They do that. It's a smaller country, and it's done. They will have good outcomes. A rare disease, getting experience is clearly an important factor in doing that.
SIOP has done some preliminary work on partial nephrectomies in unilateral Wilms tumor. While their short-term outcomes are very good and you say, well, the goal is to-you know, you get extra renal preservation, the problem is that they upstage a third of their patients. That means they have got more anthracyclines and more radiation therapy. If you actually look at the causes of renal failure in that slide in the patients with unilateral Wilms tumor, it's due to the exposure to radiation and anthracyclines.
So it's a little mixed in terms of whether they are able to achieve more than we are. I think they do a great job in regionalization. They have multiple diverse countries with diverse languages and much less resources and have excellent outcomes. It's unclear whether they say they do it different. This is a good benchmark study. It's someplace to start. But other than that, I think that's where we have to stop.
Dr Andrew Davidoff (Memphis, TN):
I guess my study was referred to enough that I feel obligated to comment. It is striking that in your study only 39% of the patients were able to undergo bilateral nephron sparing procedures. As you mentioned, in our study of over 40 patients at a single institution, we were able to do that in 90 plus percent of the cases. Additionally, I think we saw a highly selected patient population with complex anatomy. That's why they were referred to us. So I do think that it is possible to get a higher rate of bilateral nephron sparing procedures accomplished, done safely and with good oncologic outcomes. It takes a commitment to this approach.
As you mentioned, we believe that preoperative imaging is not very predictive of what you can accomplish at the time of surgery. So you really need to go into each operation without preconceived notions about what can be done.
I'll just leave it by saying I think there is something to be said for regionalization if we think it is important to peform bilateral nephron sparing surgery. If you go through the numbers, there are 30 to 40 cases of bilateral Wilms tumor in the United States each year. There may be 800 pediatric surgeons and a similar number of pediatric urologists. If you do the math, that's maybe 1 to 2 cases of bilateral Wilms tumor seen by any given surgeon during the course of their career. So I think to gain some experience, perhaps a referral to centers of excellence is appropriate.
